Castration Resistant Prostatic Neoplasms Recruiting Phase 1 / 2 Trials for Enzalutamide (DB08899)

Also known as: Prostate Neoplasms, Castration-resistant / Castration-Resistant Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant

Indication	Status	Phase
DBCOND0129140 (Castration Resistant Prostatic Neoplasms)	Recruiting	1 / 2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer	Treatment	Docetaxel (DB01248) Enzalutamide (DB08899) Etrumadenant (DB17506) Sacituzumab govitecan (DB12893) Zimberelimab (DB17505)
NCT05252390	NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Treatment	Enzalutamide (DB08899) Olaparib (DB09074)